Company: LBRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001193125-25-268174
Chunk: 1

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-11-06
Form: 10-Q
Item: Item 1
Chunk 1
---
, 2025 and December 31, 2024, respectively.  Liquidation preference of zero and $8,407 as of September 30, 2025 and December 31, 2024, respectively.

     —

     6,179

     Series B preferred stock, $0.0001 par value, zero and 301,119 shares authorized, zero and 301,119 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.  Liquidation preference of zero and $903 as of September 30, 2025 and December 31, 2024, respectively.

     —

     580

     Series C preferred stock, $0.0001 par value, zero and 75,000,000 shares authorized,  zero and 73,820,346 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively. Liquidation preference of zero and $110,731 as of September 30, 2025 and December 31, 2024, respectively.

     —

     107,065

     Stockholders’ equity (deficit)

     Common stock, $0.0001 par value, 500,000,000 and 105,000,000 shares authorized, 25,299,102 and 251,655 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively.

     3

     1

     Additional paid-in capital

     428,327

     9,657

     Accumulated deficit

     (118,056
     )

     (104,323
     )

     Accumulated other comprehensive (loss) income

     (53
     )

     111

     Total stockholders’ deficit

     310,221

     (94,554
     )

     Total liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)
      
     $
     320,746

     $
     33,534

(1) Shares authorized, shares issued and outstanding are not adjusted for the reverse stock split detailed in Note 1 Business Overview.

See accompanying notes to the unaudited condensed financial statements.